

## **Prior Authorization**

## JOHNS HOPKINS HEALTH PLANS

CGM Devices - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at <b>1-410-424-4607</b> . Please contact Johns Hopkins Health Plans at <b>1-888-819-1043</b> with questions regarding the Prior Authorization process.  When conditions are met, we will authorize the coverage of CGM Devices - Priority Partners MCO.						
vvnen conditions are r	net, we will authorize the covera	ge of CGM Devices - Priority	Partners MCO.			
Drug Name (specify drug)						
Quantity	Frequency	Strengtl	า			
Route of Administration	Expected Length of Therapy					
Patient Information Patient Name: Patient ID: Patient Group No.: Patient DOB: Patient Phone:						
Prescribing Physician Physician Name: Physician Phone: Physician Fax: Physician Address: City, State, Zip:						
Diagnosis:	ICD Co	de:				
Comments:						
Please circle the appropriate a	<u> </u>					
Is this request for con	.,	Y N				
guarantee coverage	hysician samples, or manufa e under the provisions of the ust be met in order to be elig	medical and/or pharma	cy benefit. All			
[If no, then skip to o	uestion 3.]					
	clinical improvement from u Monitoring (CGM) device?	ising the YN				

[]	Note: Documentation must be submitted.]			
[]	lo further questions.]			
	es the patient have the diagnosis of type 1 diabetes or e 2 diabetes?	Υ	N	
7]	Note: Documentation must be submitted.]			
[11]	f no, then no further questions.]			
the	es the patient require 3 or more insulin injections daily or use of an insulin pump to maintain blood glucose trol?	· Y	N	
[]	Note: Documentation must be submitted.]			
[H]	f no, then no further questions.]			
freq thar ano	es the patient have at least one of the following: A) uent severe hypoglycemia (blood glucose level less of 50 mg/dl), B) hypoglycemic unawareness requiring ther person's assistance for glucose rescue action, C) noglobin A1c greater than or equal to 7 percent?	Υ	N	
7]	lote: Documentation must be submitted.]			
[11	f no, then no further questions.]			
and (CG	the patient or caregiver received diabetes education training on using Continuous Glucose Monitoring (SM) devices, and will be sharing device readings with provider?	Y	N	
[]	Note: Documentation must be submitted.]			
[11	f no, then no further questions.]			
	nis request for a formulary Dexcom or Freestyle Libre duct?	Y	N	
[H	f no, then skip to question 11.]			
limirece Dex G7 box read box mor Fred	es the request include a quantity that exceeds the Plant? (Plan Quantity Limits: Dexcom G6 Receiver: 1 eiver/12 months; Dexcom G6 Sensor: 3 boxes/30 days; com G6 Transmitter: 1 transmitter/90 days; Dexcom Receiver: 1 receiver/12 months; Dexcom G7 Sensor: 3 es/30 days; Freestyle Libre 14-Day Reader: 1 der/12 months; Freestyle Libre 14-Day Sensor: 2 es/28 days; Freestyle Libre 2 Reader: 1 reader/12 nths; Freestyle Libre 2 Sensor: 2 boxes/28 days; estyle Libre 3 Reader: 1 reader/12 months; Freestyle es 3 Sensor: 2 boxes/28 days)	Y	N	
_	f no, then no further questions.]			
of a	es the patient require a quantity limit exception because need for replacement due to lost, stolen, or damaged duct?	Y	N	
[]	Note: Documentation must be submitted.]			
[]	f yes, then no further questions.]			
10. Doe	es the patient require a quantity limit exception because	Υ	N	

of a need for an early vacation supply?	
[Note: Documentation must be submitted]	
[No further questions.]	
11. Is this request for a non-formulary Continuous Glucose Monitoring (CGM) product?	YN
[If no, then no further questions.]	
12. Has clinical rationale been provided indicating why the patient is unable to use the formulary Continuous Glucose Monitoring (CGM) products, and how the non-formulary product is medically necessary?	Y N
[Note: Documentation must be submitted.]	
[If no, then no further questions.]	
13. Is the patient using an insulin pump?	YN
[If no, then no further questions.]	
14. Is the patient currently using an insulin pump that is paired with the non-formulary Continuous Glucose Monitoring (CGM) product being requested?	Y N
[Note: Documentation must be submitted.]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date	